Sanda M G
Department of Urology, Ann Arbor Veterans Administration Medical Center, MI, USA.
Semin Urol Oncol. 1997 Feb;15(1):43-55.
Several clinical trials of prostate cancer gene therapy are underway. The therapeutic genes being evaluated by these and other, forthcoming, trials include immunogenes, cell death-inducing genes, antioncogenes, and tumor suppressor genes. Constraints of current gene transfer vectors limit, to local-regional targeting, those gene therapy strategies that do not rely on an intervening immune response. Preclinical models predict modest, if any, therapeutic effects with current forms of prostate cancer gene therapy. Using biological surrogate endpoints and applying further preclinical advances will allow clinical prostate cancer gene therapy to attain its full potential.
多项前列腺癌基因治疗的临床试验正在进行中。这些试验以及其他即将开展的试验所评估的治疗性基因包括免疫基因、诱导细胞死亡基因、抗癌基因和肿瘤抑制基因。当前基因转移载体的局限性使得那些不依赖介入性免疫反应的基因治疗策略只能局限于局部区域靶向治疗。临床前模型预测，目前形式的前列腺癌基因治疗即便有治疗效果，也较为有限。利用生物学替代终点并应用进一步的临床前进展将使临床前列腺癌基因治疗发挥其全部潜力。
